Georgia Doris Tomaras, PhD

Print

email this


Associate Professor of Surgery
Associate Research Professor in Molecular Genetics and Microbiology
Associate Professor in Immunology
Department / Division:
Surgery / Surgical Sciences
Address:
Rm 4079 Msrb Ii
106 Research Drive
Durham, NC 27710
Office Telephone:
(919) 681-5598
Training:
  • PhD, SUNY Upstate Medical University, 1998
Research Interests:
Dr. Tomaras' overall research program is to understand the cellular and humoral immune response to HIV-1 infection and vaccination that are involved in protection from HIV-1. The research in the Tomaras laboratory centers around three main projects involving 1) antiviral CD8+ T cell responses in HIV-1 infection and post vaccination, 2) mucosal and systemic antibody responses to infection and vaccination in both non-human primates and humans and 3) the ontogeny of neutralizing antibodies in HIV-1 infection. Her laboratory is also within the Duke Human Vaccine Institute (http://humanvaccine.duke.edu/modules/Tomaras/index.php?id=1).
Antiviral CD8+ T Cell Responses. CD8+ T cell immune responses to HIV involve noncytolytic CD8 T cells that mediate suppression of HIV replication. During human acute HIV-1 infection and acute SIV infection in non-human primates, CD8+ T cell responses have been associated with the initial control of viremia. A detailed understanding of the properties of CD8+ T cells that correlate with virologic control will inform vaccine development by focusing on strategies that elicit functional cellular responses. In this regard, it is critical to determine the phenotypic and functional properties of CD8+ T cells that can mediate viral suppression. We have developed a robust and high throughput multi-clade virus inhibition assay for the measurement of functional CD8 T cell activity to decipher the mechanisms of virus inhibition that include both lytic and nonlytic mechanism. We identified that CD8+ T cell mediated virus inhibition, like other memory CD8+ T cells, can use epigenetics to control expression of inhibitory molecules so that they can control molecules released to target infected CD4+ T cells. Studying the role of epigenetics in CD8+ T cell mediated virus inhibition is an innovative concept that will likely uncover pathways for induction of highly functional CD8+ T cells. Insights into the induction of these CD8+ T cell responses are central to understanding how to precisely target this population of cells by vaccination. We found that CD8+ T cell antiviral activity from vaccinees and virus controllers were defined by CD107a and MIP-1β expression and that CD8+ T cell from all memory stages of differentiation exhibit antiviral activity, including transitional memory CD8+ T cells. Our data define attributes of an antiviral CD8+ T cell response that may be optimized in the search for an efficacious HIV-1 vaccine. Current work aims to probe the specific CD8 T cell populations that are responsible for mediating HIV-1 inhibition and the contribution of soluble factors during acute infection, in natural virus controllers, and post vaccination.
Mucosal and Systemic Antibodies. A window of opportunity for immune responses to extinguish HIV-1 exists from the moment of transmission through establishment of the latent pool of HIV-1-infected cells. A critical time to study the initial immune responses to the transmitted/founder virus is the eclipse phase of HIV-1 infection. We have shown that the first detectable antibody response is in the form of HIV-1 virion-Ab complexes and the initial free antibody response is targeted only to the gp41 portion of the HIV-1 envelope. This body of work provided a deeper understanding of the initial B cell response to HIV infection that has allowed subsequent work to focus on why the humoral response is targeted initially to gp41 and not other potentially protective epitopes. Moreover, this work is leading to more detailed analyses of the ontogeny of the initial B cell response and whether this pathway to an ineffectual antibody response impedes the elicitation of more protective responses. This is critical for defining what a vaccine must do differently from natural infection in stimulating the B cell response. We are currently working to understand the functional significance of systemic and mucosal HIV-1 specific IgM, IgG
Representative Publications:
  • Bonsignori, M; Wiehe, K; Grimm, SK; Lynch, R; Yang, G; Kozink, DM; Perrin, F; Cooper, AJ; Hwang, KK; Chen, X; Liu, M; McKee, K; Parks, RJ; Eudailey, J; Wang, M; Clowse, M; Criscione-Schreiber, LG; Moody, MA; Ackerman, ME; Boyd, SD; Gao, F; Kelsoe, G; Verkoczy, L; Tomaras, GD; Liao, HX; Kepler, TB; Montefiori, DC; Mascola, JR; Haynes, BF. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. Journal of Clinical Investigation. 2014;124:1835-1843.  Abstract
  • Dennison, SM; Anasti, KM; Jaeger, FH; Stewart, SM; Pollara, J; Liu, P; Kunz, EL; Zhang, R; Vandergrift, N; Permar, S; Ferrari, G; Tomaras, GD; Bonsignori, M; Michael, NL; Kim, JH; Kaewkungwal, J; Nitayaphan, S; Pitisuttithum, P; Rerks-Ngarm, S; Liao, HX; Haynes, BF; Alam, SM. Vaccine induced HIV-1 envelope gp120 Constant Region 1-specific Antibodies Expose a CD4-inducible Epitope and Block the Interaction of HIV-1 gp140 With Galactosylceramide. Journal of Virology. 2014;  Abstract
  • Gartland, AJ; Li, S; McNevin, J; Tomaras, GD; Gottardo, R; Janes, H; Fong, Y; Morris, D; Geraghty, DE; Kijak, GH; Edlefsen, PT; Frahm, N; Larsen, BB; Tovanabutra, S; Sanders-Buell, E; deCamp, AC; Magaret, CA; Ahmed, H; Goodridge, JP; Chen, L; Konopa, P; Nariya, S; Stoddard, JN; Wong, K; Zhao, H; Deng, W; Maust, BS; Bose, M; Howell, S; Bates, A; Lazzaro, M; O'Sullivan, A; Lei, E; Bradfield, A; Ibitamuno, G; Assawadarachai, V; O'Connell, RJ; deSouza, MS; Nitayaphan, S; Rerks-Ngarm, S; Robb, ML; Sidney, J; Sette, A; Zolla-Pazner, S; Montefiori, D; McElrath, MJ; Mullins, JI; Kim, JH; Gilbert, PB; Hertz, T. Analysis of HLAA*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. Journal of Virology. 2014;  Abstract
  • Goepfert, PA; Elizaga, ML; Seaton, K; Tomaras, GD; Montefiori, DC; Sato, A; Hural, J; DeRosa, SC; Kalams, SA; McElrath, MJ; Keefer, MC; Baden, LR; Lama, JR; Sanchez, J; Mulligan, MJ; Buchbinder, SP; Hammer, SM; Koblin, BA; Pensiero, M; Butler, C; Moss, B; Robinson, HL; HVTN 205 Study Group, ; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network. Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles. Journal of Infectious Diseases. 2014;210:99-110.  Abstract
  • Liu, P; Williams, LD; Shen, X; Bonsignori, M; Vandergrift, NA; Overman, RG; Moody, MA; Liao, HX; Stieh, DJ; McCotter, KL; French, AL; Hope, TJ; Shattock, R; Haynes, BF; Tomaras, GD. Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. Journal of Virology. 2014;88:5165-5170.  Abstract
  • Moody, MA; Santra, S; Vandergrift, NA; Sutherland, LL; Gurley, TC; Drinker, MS; Allen, AA; Xia, SM; Meyerhoff, RR; Parks, R; Lloyd, KE; Easterhoff, D; Alam, SM; Liao, HX; Ward, BM; Ferrari, G; Montefiori, DC; Tomaras, GD; Seder, RA; Letvin, NL; Haynes, BF. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. Journal of Virology. 2014;88:3329-3339.  Abstract
  • Payne, TL; Blackinton, J; Frisbee, A; Pickeral, J; Sawant, S; Vandergrift, NA; Freel, SA; Ferrari, G; Keene, JD; Tomaras, GD. Transcriptional and Post-transcriptional Regulation of Cytokine Gene Expression in HIV-1 Antigen-specific CD8+ T Cells that Mediate Virus Inhibition. Journal of Virology. 2014;  Abstract
  • Pollara, J; Bonsignori, M; Moody, MA; Liu, P; Alam, SM; Hwang, KK; Gurley, TC; Kozink, DM; Armand, LC; Marshall, DJ; Whitesides, JF; Kaewkungwal, J; Nitayaphan, S; Pitisuttithum, P; Rerks-Ngarm, S; Robb, ML; O'Connell, RJ; Kim, JH; Michael, NL; Montefiori, DC; Tomaras, GD; Liao, HX; Haynes, BF; Ferrari, G. HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. Journal of Virology. 2014;88:7715-7726.  Abstract
  • Roederer, M; Keele, BF; Schmidt, SD; Mason, RD; Welles, HC; Fischer, W; Labranche, C; Foulds, KE; Louder, MK; Yang, Z-Y; Todd, J-PM; Buzby, AP; Mach, LV; Shen, L; Seaton, KE; Ward, BM; Bailer, RT; Gottardo, R; Gu, W; Ferrari, G; Alam, SM; Denny, TN; Montefiori, DC; Tomaras, GD; Korber, BT; Nason, MC; Seder, RA; Koup, RA; Letvin, NL; Rao, SS; Nabel, GJ; Mascola, JR. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505:502-508.  
  • Roederer, M; Keele, BF; Schmidt, SD; Mason, RD; Welles, HC; Fischer, W; Labranche, C; Foulds, KE; Louder, MK; Yang, ZY; Todd, JP; Buzby, AP; Mach, LV; Shen, L; Seaton, KE; Ward, BM; Bailer, RT; Gottardo, R; Gu, W; Ferrari, G; Alam, SM; Denny, TN; Montefiori, DC; Tomaras, GD; Korber, BT; Nason, MC; Seder, RA; Koup, RA; Letvin, NL; Rao, SS; Nabel, GJ; Mascola, JR. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 2014;505:502-508.  Abstract
  • Tomaras, GD; Haynes, BF. Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. Nature Medicine. 2014;20:583-585.  Abstract
  • Tomaras, GD; Montefiori, DC. Spectrum of HIV antibodies in vaccine and disease. Current Opinion in HIV and AIDS. 2014;9:207-209.  Abstract
  • Yates, NL; Liao, HX; Fong, Y; deCamp, A; Vandergrift, NA; Williams, WT; Alam, SM; Ferrari, G; Yang, ZY; Seaton, KE; Berman, PW; Alpert, MD; Evans, DT; O'Connell, RJ; Francis, D; Sinangil, F; Lee, C; Nitayaphan, S; Rerks-Ngarm, S; Kaewkungwal, J; Pitisuttithum, P; Tartaglia, J; Pinter, A; Zolla-Pazner, S; Gilbert, PB; Nabel, GJ; Michael, NL; Kim, JH; Montefiori, DC; Haynes, BF; Tomaras, GD. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine. 2014;6:228ra39.  Abstract
  • Zolla-Pazner, S; deCamp, A; Gilbert, PB; Williams, C; Yates, NL; Williams, WT; Howington, R; Fong, Y; Morris, DE; Soderberg, KA; Irene, C; Reichman, C; Pinter, A; Parks, R; Pitisuttithum, P; Kaewkungwal, J; Rerks-Ngarm, S; Nitayaphan, S; Andrews, C; O'Connell, RJ; Yang, ZY; Nabel, GJ; Kim, JH; Michael, NL; Montefiori, DC; Liao, HX; Haynes, BF; Tomaras, GD. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. PLoS One. 2014;9:e87572.  Abstract
  • Amos, JD; Wilks, AB; Fouda, GG; Smith, SD; Colvin, L; Mahlokozera, T; Ho, C; Beck, K; Overman, RG; DeMarco, CT; Hodge, TL; LaBranche, CC; Montefiori, DC; Denny, TN; Liao, HX; Tomaras, GD; Moody, MA; Permar, SR. Lack of B cell dysfunction is associated with functional, gp120-dominant antibody responses in breast milk of simian immunodeficiency virus-infected African green monkeys. Journal of Virology. 2013;87:11121-11134.  Abstract
  • Eckels, J; Nathe, C; Nelson, EK; Shoemaker, SG; Nostrand, EV; Yates, NL; Ashley, VC; Harris, LJ; Bollenbeck, M; Fong, Y; Tomaras, GD; Piehler, B. Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform. BMC Bioinformatics. 2013;14:145.  Abstract
  • Excler, JL; Tomaras, GD; Russell, ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Current Opinion in HIV and AIDS. 2013;  Abstract
  • Excler, JL; Tomaras, GD; Russell, ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Current Opinion in HIV and AIDS. 2013;8:421-431.  
  • Fouda, GG; Amos, JD; Wilks, AB; Pollara, J; Ray, CA; Chand, A; Kunz, EL; Liebl, BE; Whitaker, K; Carville, A; Smith, S; Colvin, L; Pickup, DJ; Staats, HF; Overman, G; Eutsey-Lloyd, K; Parks, R; Chen, H; Labranche, C; Barnett, S; Tomaras, GD; Ferrari, G; Montefiori, DC; Liao, HX; Letvin, NL; Haynes, BF; Permar, SR. Mucosal immunization of lactating female rhesus monkeys with a transmitted/founder HIV-1 envelope induces strong Env-specific IgA antibody responses in breast milk. Journal of Virology. 2013;87:6986-6999.  Abstract
  • Gottardo, R; Bailer, RT; Korber, BT; Gnanakaran, S; Phillips, J; Shen, X; Tomaras, GD; Turk, E; Imholte, G; Eckler, L; Wenschuh, H; Zerweck, J; Greene, K; Gao, H; Berman, PW; Francis, D; Sinangil, F; Lee, C; Nitayaphan, S; Rerks-Ngarm, S; Kaewkungwal, J; Pitisuttithum, P; Tartaglia, J; Robb, ML; Michael, NL; Kim, JH; Zolla-Pazner, S; Haynes, BF; Mascola, JR; Self, S; Gilbert, P; Montefiori, DC. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One. 2013;8:e75665.  Abstract
  • Hammer, SM; Sobieszczyk, ME; Janes, H; Karuna, ST; Mulligan, MJ; Grove, D; Koblin, BA; Buchbinder, SP; Keefer, MC; Tomaras, GD; Frahm, N; Hural, J; Anude, C; Graham, BS; Enama, ME; Adams, E; DeJesus, E; Novak, RM; Frank, I; Bentley, C; Ramirez, S; Fu, R; Koup, RA; Mascola, JR; Nabel, GJ; Montefiori, DC; Kublin, J; McElrath, MJ; Corey, L; Gilbert, PB; HVTN 505 Study Team. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. New England Journal of Medicine. 2013;369:2083-2092.  Abstract
  • Imholte, GC; Sauteraud, R; Korber, B; Bailer, RT; Turk, ET; Shen, X; Tomaras, GD; Mascola, JR; Koup, RA; Montefiori, DC; Gottardo, R. A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. Journal of Immunological Methods. 2013;395:1-13.  
  • Imholte, GC; Sauteraud, R; Korber, B; Bailer, RT; Turk, ET; Shen, X; Tomaras, GD; Mascola, JR; Koup, RA; Montefiori, DC; Gottardo, R. A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. Journal of Immunological Methods. 2013;395:1-13.  Abstract
  • Kulkarni, V; Rosati, M; Valentin, A; Jalah, R; Alicea, C; Yu, L; Guan, Y; Shen, X; Tomaras, GD; LaBranche, C; Montefiori, DC; Irene, C; Prattipati, R; Pinter, A; Sullivan, SM; Pavlakis, GN; Felber, BK. Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. Human Vaccines and Immunotherapeutics. 2013;9:2069-2080.  Abstract
  • Liao, HX; Bonsignori, M; Alam, SM; McLellan, JS; Tomaras, GD; Moody, MA; Kozink, DM; Hwang, KK; Chen, X; Tsao, CY; Liu, P; Lu, X; Parks, RJ; Montefiori, DC; Ferrari, G; Pollara, J; Rao, M; Peachman, KK; Santra, S; Letvin, NL; Karasavvas, N; Yang, ZY; Dai, K; Pancera, M; Gorman, J; Wiehe, K; Nicely, NI; Rerks-Ngarm, S; Nitayaphan, S; Kaewkungwal, J; Pitisuttithum, P; Tartaglia, J; Sinangil, F; Kim, JH; Michael, NL; Kepler, TB; Kwong, PD; Mascola, JR; Nabel, GJ; Pinter, A; Zolla-Pazner, S; Haynes, BF. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity. 2013;38:176-186.  Abstract
  • Liu, P; Yates, NL; Shen, X; Bonsignori, M; Moody, MA; Liao, HX; Fong, Y; Alam, SM; Overman, RG; Denny, T; Ferrari, G; Ochsenbauer, C; Kappes, JC; Polonis, VR; Pitisuttithum, P; Kaewkungwal, J; Nitayaphan, S; Rerks-Ngarm, S; Montefiori, DC; Gilbert, P; Michael, NL; Kim, JH; Haynes, BF; Tomaras, GD. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. Journal of Virology. 2013;87:7828-7836.  Abstract
  • Patel, V; Jalah, R; Kulkarni, V; Valentin, A; Rosati, M; Alicea, C; von Gegerfelt, A; Huang, W; Guan, Y; Keele, BF; Bess, JW; Piatak, M; Lifson, JD; Williams, WT; Shen, X; Tomaras, GD; Amara, RR; Robinson, HL; Johnson, W; Broderick, KE; Sardesai, NY; Venzon, DJ; Hirsch, VM; Felber, BK; Pavlakis, GN. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proceedings of the National Academy of Sciences of USA. 2013;110:2975-2980.  Abstract
  • Pegu, P; Vaccari, M; Gordon, S; Keele, BF; Doster, M; Guan, Y; Ferrari, G; Pal, R; Ferrari, MG; Whitney, S; Hudacik, L; Billings, E; Rao, M; Montefiori, D; Tomaras, G; Alam, SM; Fenizia, C; Lifson, JD; Stablein, D; Tartaglia, J; Michael, N; Kim, J; Venzon, D; Franchini, G. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. Journal of Virology. 2013;87:1708-1719.  Abstract
  • Schiffner, T; Kong, L; Duncan, CJ; Back, JW; Benschop, JJ; Shen, X; Huang, PS; Stewart-Jones, GB; DeStefano, J; Seaman, MS; Tomaras, GD; Montefiori, DC; Schief, WR; Sattentau, QJ. Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. Journal of Virology. 2013;87:10163-10172.  Abstract
  • Tomaras, GD; Ferrari, G; Shen, X; Alam, SM; Liao, HX; Pollara, J; Bonsignori, M; Moody, MA; Fong, Y; Chen, X; Poling, B; Nicholson, CO; Zhang, R; Lu, X; Parks, R; Kaewkungwal, J; Nitayaphan, S; Pitisuttithum, P; Rerks-Ngarm, S; Gilbert, PB; Kim, JH; Michael, NL; Montefiori, DC; Haynes, BF. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proceedings of the National Academy of Sciences of USA. 2013;110:9019-9024.  Abstract
  • Yates, NL; Stacey, AR; Nolen, TL; Vandergrift, NA; Moody, MA; Montefiori, DC; Weinhold, KJ; Blattner, WA; Borrow, P; Shattock, R; Cohen, MS; Haynes, BF; Tomaras, GD. HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. Mucosal Immunology. 2013;6:692-703.  Abstract
  • Zhu, Z; Qin, HR; Chen, W; Zhao, Q; Shen, X; Schutte, R; Wang, Y; Ofek, G; Streaker, E; Prabakaran, P; Fouda, GG; Liao, H-X; Owens, J; Louder, M; Yang, Y; Klaric, K-A; Anthony Moody, M; Mascola, JR; Scott, JK; Kwong, PD; Montefiori, D; Haynes, BF; Tomaras, GD; Dimitrov, DS. Erratum to Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies [Journal of Virology, 85, 21, (2011) 11401-11408] DOI: 10.1128/JVI.05312-11. Journal of Virology. 2013;87:13936-13936.  
  • Zhu, Z; Qin, HR; Chen, W; Zhao, Q; Shen, X; Schutte, R; Wang, Y; Ofek, G; Streaker, E; Prabakaran, P; Fouda, GG; Liao, H-X; Owens, J; Louder, M; Yang, Y; Klaric, K-A; Moody, MA; Mascola, JR; Scott, JK; Kwong, PD; Montefiori, D; Haynes, BF; Tomaras, GD; Dimitrov, DS. Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies (vol 85, pg 11401, 2011). Journal of Virology. 2013;87:13936-13936.  
  • Zolla-Pazner, S; deCamp, AC; Cardozo, T; Karasavvas, N; Gottardo, R; Williams, C; Morris, DE; Tomaras, G; Rao, M; Billings, E; Berman, P; Shen, X; Andrews, C; O'Connell, RJ; Ngauy, V; Nitayaphan, S; de Souza, M; Korber, B; Koup, R; Bailer, RT; Mascola, JR; Pinter, A; Montefiori, D; Haynes, BF; Robb, ML; Rerks-Ngarm, S; Michael, NL; Gilbert, PB; Kim, JH. Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial. PLoS One. 2013;8.  Abstract
  • Churchyard, GJ; Morgan, C; Adams, E; Hural, J; Graham, BS; Moodie, Z; Grove, D; Gray, G; Bekker, LG; McElrath, MJ; Tomaras, GD; Goepfert, P; Kalams, S; Baden, LR; Lally, M; Dolin, R; Blattner, W; Kalichman, A; Figueroa, JP; Pape, J; Schechter, M; Defawe, O; De Rosa, SC; Montefiori, DC; Nabel, GJ; Corey, L; Keefer, MC; NIAID HIV Vaccine Trials Network. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One. 2011;6:e21225.  Abstract
  • De Rosa, SC; Thomas, EP; Bui, J; Huang, Y; deCamp, A; Morgan, C; Kalams, SA; Tomaras, GD; Akondy, R; Ahmed, R; Lau, CY; Graham, BS; Nabel, GJ; McElrath, MJ; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable. Journal of Immunology. 2011;187:3391-3401.  Abstract
  • Dennison, SM; Sutherland, LL; Jaeger, FH; Anasti, KM; Parks, R; Stewart, S; Bowman, C; Xia, SM; Zhang, R; Shen, X; Scearce, RM; Ofek, G; Yang, Y; Kwong, PD; Santra, S; Liao, HX; Tomaras, G; Letvin, NL; Chen, B; Alam, SM; Haynes, BF. Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41. PLoS One. 2011;6:e27824.  Abstract
  • Ferrari, G; Pollara, J; Kozink, D; Harms, T; Drinker, M; Freel, S; Moody, MA; Alam, SM; Tomaras, GD; Ochsenbauer, C; Kappes, JC; Shaw, GM; Hoxie, JA; Robinson, JE; Haynes, BF. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. Journal of Virology. 2011;85:7029-7036.  Abstract
  • Flynn, BJ; Kastenmüller, K; Wille-Reece, U; Tomaras, GD; Alam, M; Lindsay, RW; Salazar, AM; Perdiguero, B; Gomez, CE; Wagner, R; Esteban, M; Park, CG; Trumpfheller, C; Keler, T; Pantaleo, G; Steinman, RM; Seder, R. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proceedings of the National Academy of Sciences of USA. 2011;108:7131-7136.  Abstract
  • Freel, SA; Saunders, KO; Tomaras, GD. CD8(+)T-cell-mediated control of HIV-1 and SIV infection. Immunologic Research: a selective reference to current research and practice. 2011;49:135-146.  Abstract
  • Goepfert, PA; Elizaga, ML; Sato, A; Qin, L; Cardinali, M; Hay, CM; Hural, J; DeRosa, SC; DeFawe, OD; Tomaras, GD; Montefiori, DC; Xu, Y; Lai, L; Kalams, SA; Baden, LR; Frey, SE; Blattner, WA; Wyatt, LS; Moss, B; Robinson, HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. Journal of Infectious Diseases. 2011;203:610-619.  Abstract
  • Gray, ES; Moody, MA; Wibmer, CK; Chen, X; Marshall, D; Amos, J; Moore, PL; Foulger, A; Yu, JS; Lambson, B; Abdool Karim, S; Whitesides, J; Tomaras, GD; Haynes, BF; Morris, L; Liao, HX. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. Journal of Virology. 2011;85:7719-7729.  Abstract
  • Haynes, BF; Moody, MA; Liao, HX; Verkoczy, L; Tomaras, GD. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends in Molecular Medicine. 2011;17:108-116.  Abstract
  • Jiang, C; Parrish, NF; Wilen, CB; Li, H; Chen, Y; Pavlicek, JW; Berg, A; Lu, X; Song, H; Tilton, JC; Pfaff, JM; Henning, EA; Decker, JM; Moody, MA; Drinker, MS; Schutte, R; Freel, S; Tomaras, GD; Nedellec, R; Mosier, DE; Haynes, BF; Shaw, GM; Hahn, BH; Doms, RW; Gao, F. Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. Journal of Virology. 2011;85:10669-10681.  Abstract
  • Keefer, MC; Frey, SE; Elizaga, M; Metch, B; Rosa, SCD; Barroso, PF; Tomaras, G; Cardinali, M; Goepfert, P; Kalichman, A; Philippon, V; McElrath, MJ; Jin, X; Ferrari, G; Defawe, OD; Mazzara, GP; Montefiori, D; Pensiero, M; Panicali, DL; Corey, L. A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine. 2011;29:1948-1958.  Abstract
  • Moody, MA; Zhang, R; Walter, EB; Woods, CW; Ginsburg, GS; McClain, MT; Denny, TN; Chen, X; Munshaw, S; Marshall, DJ; Whitesides, JF; Drinker, MS; Amos, JD; Gurley, TC; Eudailey, JA; Foulger, A; DeRosa, KR; Parks, R; Meyerhoff, RR; Yu, JS; Kozink, DM; Barefoot, BE; Ramsburg, EA; Khurana, S; Golding, H; Vandergrift, NA; Alam, SM; Tomaras, GD; Kepler, TB; Kelsoe, G; Liao, HX; Haynes, BF. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One. 2011;6:e25797.  Abstract
  • Shen, X; Tomaras, GD. Alterations of the B-cell response by HIV-1 replication. Current HIV/AIDS Reports. 2011;8:23-30.  Abstract
  • Shen, X; Tomaras, GD. Erratum to: Alterations of the B-cell response by HIV-1 replication (Current HIV/AIDS Reports (2011) 8, (23-30) DOI: 10.1007/s11904-010-0064-2). Current HIV/AIDS Reports. 2011;8:73-.  
  • Spearman, P; Lally, MA; Elizaga, M; Montefiori, D; Tomaras, GD; McElrath, MJ; Hural, J; De Rosa, SC; Sato, A; Huang, Y; Frey, SE; Sato, P; Donnelly, J; Barnett, S; Corey, LJ; HIV Vaccine Trials Network of NIAID. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. Journal of Infectious Diseases. 2011;203:1165-1173.  Abstract
  • Tomaras, GD; Binley, JM; Gray, ES; Crooks, ET; Osawa, K; Moore, PL; Tumba, N; Tong, T; Shen, X; Yates, NL; Decker, J; Wibmer, CK; Gao, F; Alam, SM; Easterbrook, P; Abdool Karim, S; Kamanga, G; Crump, JA; Cohen, M; Shaw, GM; Mascola, JR; Haynes, BF; Montefiori, DC; Morris, L. Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. Journal of Virology. 2011;85:11502-11519.  Abstract
  • Yates, NL; Lucas, JT; Nolen, TL; Vandergrift, NA; Soderberg, KA; Seaton, KE; Denny, TN; Haynes, BF; Cohen, MS; Tomaras, GD. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS. 2011;25:2089-2097.  Abstract